Alnylam Pharmaceuticals, Inc.
ALNYFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
2,248
Cost of Revenue
323
Gross Profit
1,925
Gross Margin
85.6%
Operating Income
-177
Operating Margin
-7.9%
Net Income
-278
Net Margin
-12.4%
EPS (Basic)
$-2.18
EPS (Diluted)
$-2.18
EBITDA
-179
EBITDA Margin
-8.0%
2023
12/31/2023
Revenue
1,828
Cost of Revenue
310
Gross Profit
1,518
Gross Margin
83.0%
Operating Income
-282
Operating Margin
-15.4%
Net Income
-440
Net Margin
-24.1%
EPS (Basic)
$-3.52
EPS (Diluted)
$-3.52
EBITDA
-258
EBITDA Margin
-14.1%
2022
12/31/2022
Revenue
1,037
Cost of Revenue
169
Gross Profit
869
Gross Margin
83.7%
Operating Income
-785
Operating Margin
-75.7%
Net Income
-1,131
Net Margin
-109.0%
EPS (Basic)
$-9.30
EPS (Diluted)
$-9.30
EBITDA
-927
EBITDA Margin
-89.3%
2021
12/31/2021
Revenue
844
Cost of Revenue
140
Gross Profit
704
Gross Margin
83.4%
Operating Income
-709
Operating Margin
-83.9%
Net Income
-853
Net Margin
-101.0%
EPS (Basic)
$-7.20
EPS (Diluted)
$-7.20
EBITDA
-662
EBITDA Margin
-78.4%
2020
12/31/2020
Revenue
493
Cost of Revenue
78
Gross Profit
415
Gross Margin
84.2%
Operating Income
-828
Operating Margin
-168.1%
Net Income
-858
Net Margin
-174.1%
EPS (Basic)
$-7.46
EPS (Diluted)
$-7.46
EBITDA
-736
EBITDA Margin
-149.4%